Obesity and type 2 diabetes are associated with low-grade inflammation and specific changes in gut microbiota composition [1] [2] [3] [4] [5] [6] [7] . We previously demonstrated that administration of Akkermansia muciniphila to mice prevents the development of obesity and associated complications 8 . However, the underlying mechanisms of this protective effect remain unclear. Moreover, the sensitivity of A. muciniphila to oxygen and the presence of animal-derived compounds in its growth medium currently limit the development of translational approaches for human medicine 9 . We have addressed these issues here by showing that A. muciniphila retains its efficacy when grown on a synthetic medium compatible with human administration. Unexpectedly, we discovered that pasteurization of A. muciniphila enhanced its capacity to reduce fat mass development, insulin resistance and dyslipidemia in mice. These improvements were notably associated with a modulation of the host urinary metabolomics profile and intestinal energy absorption. We demonstrated that Amuc_1100, a specific protein isolated from the outer membrane of A. muciniphila, interacts with Toll-like receptor 2, is stable at temperatures used for pasteurization, improves the gut barrier and partly recapitulates the beneficial effects of the bacterium. Finally, we showed that administration of live or pasteurized A. muciniphila grown on the synthetic medium is safe in humans. These findings provide support for the use of different preparations of A. muciniphila as therapeutic options to target human obesity and associated disorders.
Akkermansia muciniphila is one of the most abundant members of the human gut microbiota, representing between 1% and 5% of our intestinal microbes 10, 11 . We and others recently observed that the abundance of A. muciniphila is decreased during obesity and diabetes 2, 8 and that higher baseline abundance is significantly associated with the improvement of cardiometabolic parameters in individuals with obesity undergoing caloric restriction 12 . Moreover, we found that daily administration of live A. muciniphila grown on a mucusbased medium can counteract the development of high-fat diet (HFD)-induced obesity and gut barrier dysfunction 8 , an observation later confirmed by other groups 13, 14 . However, the underlying mechanisms of these effects are still unclear. In addition, the current growth requirements of A. muciniphila and its oxygen sensitivity 9 render this bacterium unsuitable for human investigations and putative therapeutic opportunities.
Therefore, in HFD-fed mice, we compared the effects of daily administration of A. muciniphila grown either on a mucus-based medium (HFD live Akk mucus) or a synthetic medium in which mucin was replaced by a combination of glucose, N-acetylglucosamine, soy peptone and threonine (HFD live Akk synthetic). This medium allowed us to culture A. muciniphila with the same efficiency as in the mucus-based medium while avoiding any compounds that are incompatible with human administration. We observed that live A. muciniphila treatment tended to reduce HFD-induced body weight and fat mass gain (by about 40-50%). It also tended to improve glucose intolerance and insulin resistance regardless of both growth medium and food intake ( Fig. 1a-g ) . We previously showed that autoclaving A. muciniphila abolished its beneficial effects 8 . However, recent investigations suggest that probiotics inactivated by pasteurization for 30 min at 70 °C, a less extreme treatment limiting the denaturation of their cellular A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice l e t t e r s 1 0 8 VOLUME 23 | NUMBER 1 | JANUARY 2017 nature medicine components, could partly or fully retain their beneficial effects 15, 16 . Hence, we assessed the effects of A. muciniphila grown on a synthetic medium and inactivated by pasteurization (HFD pasteurized Akk). Unexpectedly, in two separate sets of experiments, we found that pasteurized A. muciniphila exerted stronger effects than the live bacterium independently of food intake, as HFD-fed mice treated with pasteurized bacteria showed similar body weight and fat mass gain to mice fed with a control diet (ND) (Fig. 1a-c and Supplementary Fig. 1a-c) .
In both sets of experiments, we found that mice treated with pasteurized A. muciniphila displayed a much lower glucose intolerance and insulin concentration when compared to the HFD group, which resulted in a lower insulin resistance (IR) index in the treated mice ( Fig. 1d-g and Supplementary Fig. 1d-g ). Treatment with pasteurized A. muciniphila also led to greater goblet cell density in the ileum than was found in ND-fed mice (Fig. 1h) ; this suggests that in HFD-fed mice treated with the pasteurized bacterium, as compared to untreated, ND-fed mice, more mucus is produced. Furthermore, when comparing mice treated with pasteurized A. muciniphila to untreated, HFD-fed mice, the mean adipocyte diameter (Fig. 2a,b ) is normalized and plasma leptin is significantly lower (Fig. 2c) . These effects were not observed in mice treated with live A. muciniphila. A similar trend was observed for plasma resistin ( Supplementary  Fig. 1h ) thereby suggesting improved insulin sensitivity, while plasma adiponectin remained unaffected in all conditions ( Supplementary  Fig. 1i ). We found that mice treated with pasteurized A. muciniphila had a higher fecal caloric content when compared to all other groups (Fig. 2d) , suggesting a lower energy absorption. This may further contribute to the reduction in body weight and fat mass gain observed in this group. Similar effects of A. muciniphila on energy absorption were previously reported in mice undergoing cold exposure 17 . Altogether, these data suggest that pasteurization enhances the beneficial effects of A. muciniphila on HFD-induced metabolic syndrome.
This could be due to increased accessibility of specific bacterial compounds that are involved in production of the positive effects of A. muciniphila on its host. Conversely, pasteurization of A. muciniphila could prevent the production of metabolites or factors that mitigate its beneficial effects. We next tested whether treatment with A. muciniphila could reduce the HFD-induced shift in the host urinary metabolome 18 . HFD was the main factor influencing 1 H-NMR-based untargeted metabolic profiles on the first O-PLS-DA score (Tpred1); treatment with pasteurized A. muciniphila clustered separately from all other groups regarding the second score (Tpred2) (Fig. 2e-g ). This resulted in a normalization of the HFD-induced shift of 37% with the pasteurized bacterium and 17% with the live bacterium (Fig. 2f) .
By comparing the metabolic profiles of the different groups, we found that the shift induced by pasteurized A. muciniphila was mainly associated with trimethylamine (TMA) and trimethylamine-N-oxide (TMAO) according to the OPLS-DA model coefficients (Supplementary Fig. 2 ). While HFD feeding severely lowered the abundance of TMA compared to ND-fed mice, treatment with pasteurized A. muciniphila significantly offset this reduction (Fig. 2h) . A similar trend was observed for urinary TMAO (Fig. 2i) . This relative increase in TMA abundance was not observed in mice treated with live A. muciniphila. Treatment with pasteurized A. muciniphila also modulated hepatic expression of Fmo3, a gene encoding flavin monooxygenase 3, which converts TMA to TMAO, a metabolite associated with atherosclerosis 19, 20 . While exposure to a HFD led to a two-fold higher Fmo3 expression as compared to that in ND-fed mice, treatment with pasteurized A. muciniphila reversed this effect (Fig. 2j) . Of note, knockdown of Fmo3 through the use of specific antisense oligonucleotides can increase serum concentration of TMA 20 and can protect mice against the development of atherosclerosis and insulin resistance 21 . Moreover, recent findings suggest that Data were analyzed using one-way ANOVA followed by Tukey post hoc test for a-c,e,g,h, and according to two-way ANOVA followed by Bonferroni post hoc test for d,f. *P < 0.05; **P < 0.01; ***P < 0.001.
oral administration of live A. muciniphila can impede the development of atherosclerosis in Apoe −/− mice 22 . In our study, however, the effects observed on urinary TMA and Fmo3 expression were not associated with a modification of plasma TMA and TMAO, as all HFD-fed mice displayed similar concentrations for both metabolites (Fig. 2k,l) . This suggests that the observed decrease in Fmo3 expression is not sufficient to inhibit the conversion of TMA to TMAO, and that the metabolic effects of pasteurized A. muciniphila are not related to these two metabolites.
Toll-like receptors (TLRs) regulate bacterial recognition and intestinal homeostasis, and they can also shape the host metabolism [23] [24] [25] . To identify how A. muciniphila interacts with its host, we performed in vitro experiments to evaluate its TLR signaling potential. Previous results suggested that A. muciniphila lipopolysaccharide (LPS) differs structurally from that of Escherichia coli and is not a powerful TLR4 agonist 26 . Here, we observed that A. muciniphila specifically activated cells expressing TLR2 (Fig. 3a) , but not cells expressing TLR5, TLR9 or the NOD2 receptor ( Fig. 3b-d) .
Genomic and proteomic analyses of A. muciniphila identified proteins encoded by a specific Type IV pili gene cluster in fractions enriched for outer membrane proteins 27 . Among these, Amuc_1100, a protein of 32 kDa, was one of the most abundant. Additionally, its presence on a gene cluster related to pilus formation suggests that it could be involved in the crosstalk with the host. To test this hypothesis, we showed that a His-tagged Amuc_1100 produced in E. coli (hereafter called Amuc_1100*) could signal to TLR2-expressing cells in a similar manner to A. muciniphila (Fig. 3a) . Furthermore, Amuc_1100* appeared relatively thermostable, as differential light scattering analysis indicated its melting temperature was 70° C (Fig. 3e) , which is the temperature applied for pasteurization. Therefore, Amuc_1100 could still be active in pasteurized bacteria and contribute to the observed signaling. Consequently, we compared the effects of the live and pasteurized bacterium to those of Amuc_1100* in HFD-fed mice. Similarly to what was observed with the pasteurized bacterium, treatment with Amuc_1100* induced a lower body weight and fat mass gain when compared to that in untreated HFD-fed mice, independently of food intake ( Fig. 3f-h ). It also tended to correct HFD-induced higher adipocyte diameter (Supplementary Fig. 3a,b) . Treatment with A. muciniphila or Amuc_1100* corrected HFD-induced hypercholesterolemia with significantly lower plasma HDL cholesterol concentrations; a similar trend was observed for LDL cholesterol (Fig. 3i) . Mice treated with pasteurized A. muciniphila displayed significantly lower plasma triglycerides concentrations than either untreated mice or HFD-fed mice treated with live A. muciniphila, again suggesting an increased potency of the bacterium after pasteurization (Fig. 3j) . No differences were observed in the distribution of triglycerides and cholesterol in lipoproteins (Supplementary Fig. 3c,d ). Amuc_1100* also improved glucose tolerance with the same potency as the live and pasteurized bacterium (Fig. 3k,l) . To further investigate the effects of A. muciniphila on insulin sensitivity, we analyzed insulin-induced phosphorylation of the insulin receptor (IR) and its downstream mediator Akt at the threonine (Akt thr ) and serine (Akt ser ) sites 28 in the liver (Fig. 3m,n) . As previously described, untreated HFD-fed mice displayed lower phosphorylation of all analyzed proteins when compared to ND-fed mice 29 , an effect that reached significance for Akt thr (Fig. 3n) . Treatment with A. muciniphila or Amuc_1100* counteracted these effects, with significantly higher levels of p-IR and p-Akt thr in mice treated with Amuc_1100* (Fig. 3m,n) , and significantly higher levels of p-Akt ser in mice treated with the live bacterium (Fig. 3n ) when compared to untreated HFD-fed mice.
Previous reports show that beneficial effects of A. muciniphila are associated with improvements of the gut barrier function 8, 13, 22, 26 leading to a correction of metabolic endotoxemia (i.e., increased portal LPS concentration) in obese and diabetic mice. We therefore assessed the effects of pasteurized A. muciniphila and Amuc_1100* on endotoxemia and genes associated with the intestinal barrier. While HFD-fed mice displayed higher portal LPS concentration than ND-fed mice, treatment with Akkermansia-either live or pasteurized-or Amuc_1100* completely restored LPS concentration to that observed in the ND group (Fig. 4a) . Among the assessed markers of the gut barrier, we found that expression of Cnr1, coding for cannabinoid receptor 1 (CB 1 ), was specifically lower in the jejunum of mice treated with Amuc_1100* (Fig. 4b) . Interestingly, activation of CB 1 was shown to increase intestinal permeability in vitro, whereas blocking CB 1 reduces gut permeability both in vitro and in vivo 30 . In accordance with these findings, genes encoding tight-junction proteins involved in the regulation of intestinal permeability were also affected. In the jejunum, expression of Cldn3 (encoding claudin 3) was higher in mice treated with Amuc_1100* when compared to untreated HFD-fed mice (Fig. 4b) ; in contrast, expression of Ocln (encoding occludin) was higher in all treated groups when compared to ND-fed mice, as well as in mice receiving Amuc_1100* when compared to untreated HFD-fed mice (Fig. 4b) . In the ileum, a trend for lower Cnr1 expression was observed following treatment with A. muciniphila (Fig. 4c) . Cldn3 expression was greater in all treated groups when compared to untreated ND-and HFD-fed mice, while Ocln was unaffected (Fig. 4c) . These effects could notably be explained by the ability of A. muciniphila to activate TLR2 via Amuc_1100, as this receptor can regulate various tight-junction proteins including occludin and claudin 3 (refs. 31,32) . In the colon, untreated HFD-fed mice had a higher Ocln expression as compared to the other groups, whereas Cnr1 tended to be higher in all HFD-fed groups and Cldn3 was not modified (Supplementary Fig. 4a) .
We next assessed markers of the synthesis (Napepld) and the degradation (Naaa) of different endocannabinoids and bioactive lipids from the N-acylethanolamine (NAEs) family 33 . Napepld expression was lower specifically in the jejunum following treatment with pasteurized A. muciniphila when compared to that in ND-fed mice or in mice treated with Amuc_1100* (Supplementary Fig. 4b) . Naaa, however, was not modified by any treatment in all intestinal segments ( Supplementary Fig. 4b-d) . Therefore, this set of data suggests that Amuc_1100* and pasteurized A. muciniphila exhibit distinct mechanisms of action on the endocannabinoid system.
Antimicrobial peptides are also contributing to the gut barrier function by shaping the gut microbiota 34 . We found that mice treated with pasteurized A. muciniphila had significantly higher Lyz1 expression in both the jejunum and ileum when compared to ND-fed mice, while Amuc_1100* did not significantly affect this parameter (Fig. 4d,e) . We observed a significantly lower DefA expression in the jejunum of mice treated with pasteurized A. muciniphila and Amuc_1100* as compared to ND-fed mice (Fig. 4d) . In the ileum, mice treated with Amuc_1100* had significantly lower DefA expression than mice treated with either live or pasteurized A. muciniphila (Fig. 4e) . This again suggests different mechanisms of action of Amuc_1100* and pasteurized A. muciniphila, in this case on antimicrobial peptides. However, treatment with A. muciniphila or Amuc_1100* did not change the HFD-mediated lower Reg3g and Pla2g2 expression (Fig. 4d,e and Supplementary Fig. 4e) . Altogether, these results suggest that Amuc_1100* and pasteurized A. muciniphila act on Figures 6 and 7 . Data are presented as the mean ± s.e.m. Data in a,c,d represent three independent experiments, except for low concentrations of Amuc_1100* (0.05 and 0.5 µg/ml), where two independent experiments were performed. Data in b represent two independent experiments. Number of mice per group for f,g,i,k,l: ND: 9, HFD: 8, HFD live Akk synthetic: 8, HFD pasteurized Akk: 10, HFD Amuc_1100*: 10. For h, five measurements were obtained for each group. Number of mice per group for j: ND: 9, HFD: 8, HFD live Akk synthetic: 8, HFD pasteurized Akk: 10, HFD Amuc_1100*: 9. Number of mice per group for m,n: ND: 8, HFD: 9, HFD live Akk synthetic: 9, HFD pasteurized Akk: 9, HFD Amuc_1100*: 9. Data were analyzed using one-way ANOVA followed by Dunnett post hoc test versus DMEM condition for a,c,d, using Kruskal-Wallis followed by Dunn post hoc test versus DMEM condition for b, according to one-way ANOVA followed by Tukey post hoc test for f-h,j,l, and according to two-way ANOVA followed by Bonferroni post hoc test for i,k,m,n.*P < 0.05; **P < 0.01; ***P < 0.001. different targets to reinforce the intestinal barrier in the jejunum and ileum; this could explain the correction of HFD-induced metabolic endotoxemia in treated mice.
Finally, we evaluated the safety and tolerability of A. muciniphila in individuals with excess body weight by treating them with different doses of live A. muciniphila (Akk synthetic, 10 10 or 10 9 ) or pasteurized A. muciniphila (Akk pasteurized, 10 10 ) as part of an ongoing clinical study testing the efficacy of this bacterium on metabolic parameters associated with obesity and the metabolic syndrome. Subjects are currently being recruited and analyzed, and complete results will be reported once the study is complete (at the end of 2017). Anthropomorphic characteristics of the subjects at the beginning of treatment are reported in Supplementary Table 1 . We analyzed several clinical parameters measured in probiotics safety assessments [35] [36] [37] before and after 2 weeks of treatment. No significant changes on markers related to inflammation and hematology, kidney, liver and muscle function were observed with any formulation of A. muciniphila (Supplementary Fig. 5 and Supplementary Table 2) . Moreover, the frequency of recorded adverse effects was similar in all groups (Supplementary Table 3 muciniphila, but the difference with other groups was not significant. While the number of subjects is limited, these first human data suggest that both live and pasteurized A. muciniphila are well tolerated in subjects with excess body weight and appear safe for oral administration in the context of obesity.
A. muciniphila is a promising target in the management of obesity and related disorders. Several studies have shown positive associations between A. muciniphila and the host metabolic health. Moreover, various dietary interventions targeting obesity and glucose intolerance increase A. muciniphila abundance 8, 34, 38 , as does the glucose-lowering drug metformin 3, 13 . To our knowledge, A. muciniphila is currently unique in the field of next-generation probiotic research as it resides in the mucus layer, a niche in close vicinity of host cells, and because it displays beneficial effects on several pathologies. Direct administration has proven protective not only against obesity but also against type 2 diabetes, gut barrier disturbances as well as atherosclerosis in various studies 8, 13, 14, 22 . Moreover, metagenomics data suggest that A. muciniphila abundance could also be inversely associated with type 1 diabetes and inflammatory bowel disorders 39, 40 . However, translational evaluation of A. muciniphila for human therapeutics is hampered by the requirement for animal-derived compounds in the growth medium of the bacterium. To circumvent this issue, we tested the effects of A. muciniphila grown on a synthetic medium compatible with human administration. We show in mice that effects on obesity and glucose metabolism are generally conserved when compared to the bacterium grown on a mucus-based medium.
Another hurdle to the use of live A. muciniphila in human subjects is its high sensitivity to oxygen. Here, we show that non-replicative, pasteurized A. muciniphila had stronger effects on body weight gain, fat mass gain and glucose intolerance in HFD-fed mice. These effects are associated with specific modulations of the host urinary metabolome, decreased intestinal energy absorption, normalization of plasma LPS concentration and decreased triglyceridemia. Moreover, we show that the outer membrane protein Amuc_1100* is involved in the A.-muciniphila-to-host interaction through TLR2 signaling, and that it partially recapitulates the effects of A. muciniphila against obesity, insulin resistance and gut barrier alteration. How pasteurization enhances the effects of A. muciniphila remains to be elucidated. The fact that Amuc_1100* is still stable at 70 °C suggests it could still be signaling in pasteurized cells and that pasteurization enhances the effects of A. muciniphila by increasing accessibility of this protein to the host. Whether this improvement of beneficial effects through pasteurization is specific to A. muciniphila, or could be extended to other bacteria, also needs to be tested. Regardless, pasteurization could represent an innovative way to use anaerobic strains as a therapeutic tool. Moreover, identification and isolation of specific bacterial products recapitulating all or part of the effects of the live organism could prove useful in the treatment of conditions such as inflammatory bowel diseases, where direct administration of live probiotics would be challenging.
Finally, preliminary human data suggest that treatment with either live or pasteurized A. muciniphila grown on the synthetic medium is safe in individuals with excess body weight, as no changes in relevant safety clinical parameters or reported adverse events were observed after two weeks of treatment. These results pave the way for future human studies investigating A. muciniphila as a therapeutic tool in the management of the metabolic syndrome.
MeTHOdS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Number of mice per group for c and e: ND: 9, HFD: 7, HFD live Akk synthetic: 8, HFD pasteurized Akk: 9, HFD Amuc_1100*: 9. Data were analyzed using one-way ANOVA followed by Tukey post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. T., screened the subjects and contributed to follow-up. A.E., C. Druart, C. Depommier and P.D.C. followed subjects during the study. All authors discussed results and approved the manuscript.
ONLINe MeTHOdS
Culture and pasteurization of Akkermansia muciniphila. A. muciniphila MucT (ATTC BAA-835) was cultured anaerobically in a basal mucin-based medium as previously described 9 , or in a synthetic medium where mucin was replaced by 16 g/l soy-peptone, 4 g/l threonine, and a mix of glucose and N-acetylglucosamine (25 mM each). Cultures were washed and concentrated in anaerobic PBS with 25% (vol/vol) glycerol under strict anaerobic conditions. Additionally, an identical quantity of A. muciniphila grown on the synthetic medium was inactivated by pasteurization for 30 min at 70 °C. Cultures were then immediately frozen and stored at −80 °C. A representative glycerol stock was thawed under anaerobic conditions to determine the CFU/ml by plate counting using mucin media containing 1% agarose (agar noble; Difco). Before administration by oral gavage, glycerol stocks were thawed under anaerobic conditions and diluted with anaerobic PBS to an end concentration of 2 × 10 8 CFU/150 µl and 2.5% glycerol.
Mice. Cohorts of 10-to 11-week-old male C57BL/6J mice (Charles River, L' Arbresle, France) were housed in a controlled environment (12 h daylight cycle, lights off at 6 p.m.) in groups of two mice per cage, with free access to food and water. Upon delivery, mice underwent an acclimation period of one week, during which they were fed a control diet (ND) (AIN93Mi, Research Diet, New Brunswick, NJ, USA). Mice were fed a normal chow diet (ND) (AIN93Mi, Research diet, New Brunswick, NJ, USA) or a high-fat diet (HFD) (60% fat and 20% carbohydrates (kcal/100g) D12492i, Research diet, New Brunswick, NJ, USA). Body weight, food and water intake were recorded once weekly. Body composition was assessed by using 7.5 MHz time domainnuclear magnetic resonance (TD-NMR) (LF50 Minispec, Bruker, Rheinstetten, Germany). Mice experiments were not performed in a blinded manner. For the first experiment, mice were treated daily with an oral administration of A. muciniphila grown on the mucus-based medium (HFD Akk M) or the synthetic medium (HFD Akk S). Additionally, one group of mice was treated daily with an oral administration of pasteurized A. muciniphila (HFD Akk P). Control groups (ND and HFD) were treated with an oral gavage of an equivalent volume of sterile PBS containing 2.5% glycerol. Treatment was continued for 4 weeks.
For the second experiment, mice were treated daily with an oral administration of either live or pasteurized A. muciniphila grown on the synthetic medium (HFD Akk S and HFD Akk P, respectively). Control groups (ND and HFD) were treated with an oral gavage of an equivalent volume of sterile PBS containing 2.5% glycerol. Treatment was continued for 5 weeks. Fresh urinary samples were collected during the final week of treatment and directly stored at −80 °C before analysis. Circulating leptin and resistin concentrations were determined using a multiplex immunoassay kit (Merck Millipore, Brussels, Belgium) and measured using Luminex technology (Bioplex, Bio-Rad, Belgium) following the manufacturer's instructions. Circulating adiponectin concentrations were determined using an ELISA kit (R&D Systems, Minneapolis, Minnesota, USA). Fecal energy content was measured on fecal samples harvested after a 24 h period during the final week of treatment by the use of a bomb calorimeter (Mouse Clinical Institute, Illkirch, France).
For the third experiment, mice were treated daily with an oral administration of either live or pasteurized A. muciniphila grown on the synthetic medium (HFD Akk S and HFD Akk P, respectively). Additionally, one group of mice was treated with a daily oral administration of 3 µg of the protein Amuc_1100* (see below) in an equivalent volume of sterile PBS containing 2.5% glycerol. This dose of Amuc_1100* was estimated to be equivalent to 1.5 × 10 8 CFU of A. muciniphila through the use of an in-house polyclonal antibody. Control groups (ND and HFD) were treated with an oral gavage of an equivalent volume of sterile PBS containing 2.5% glycerol. Treatment was continued for 5 weeks.
All mouse experiments were approved by and performed in accordance with the guidelines of the local ethics committee. Housing conditions were specified by the Belgian Law of May 29, 2013 , regarding the protection of laboratory animals (agreement number LA1230314).
Exclusion criteria were predefined as follows: Mice displaying abnormal behavior when on a HFD (for example, increased aggressiveness leading to alteration of food intake and/or body weight loss) during the follow-up period were excluded from analyses. All tissues were carefully examined during necropsy and sampling. Any mouse displaying lesions (for example, granulous liver) was also excluded. Finally, for all analyses and for each group, any exclusion decision was supported by the use of the Grubbs test for outlier detection. Moreover, during the second experiment, two mice from the same cage in the group HFD Akk S were excluded from analysis of the OGTT and insulin data displayed in Supplementary Figure 1d -g, because of aggressiveness and fighting throughout the OGTT leading to abnormal blood glucose and insulin values.
Oral glucose tolerance test. 6-h-fasted mice were treated with an oral gavage glucose load (2 g glucose per kg body weight). Blood glucose was measured before oral glucose load and 15, 30, 60, 90 and 120 min after oral glucose load. Blood glucose was determined with a glucose meter (Accu Check, Roche, Switzerland) on blood samples collected from the tip of the tail vein.
Insulin resistance index. Plasma insulin concentration was determined on samples using an ELISA kit (Mercodia, Uppsala, Sweden) according to the manufacturer's instructions. Insulin resistance index was determined by multiplying the area under the curve of both blood glucose (−30 to 120 min) and plasma insulin (−30 and 15 min) obtained following the oral glucose tolerance test.
